Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk

Petenkaya A., Bozkurt B., Akilli-Ozturk O., Kaya H. S., Gur-Dedeoglu B., Yulug I. G.

ANTICANCER RESEARCH, cilt.26, sa.6C, ss.4975-4977, 2006 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 26 Sayı: 6C
  • Basım Tarihi: 2006
  • Dergi Adı: ANTICANCER RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.4975-4977
  • Anahtar Kelimeler: MDM2 polymorphism, breast cancer, SINGLE NUCLEOTIDE POLYMORPHISM, ACCELERATES TUMOR-FORMATION, MDM2 SNP309, P53, PROMOTER
  • Ankara Üniversitesi Adresli: Hayır

Özet

Background: A T-to-G polymorphism (SNP309) at the promoter region of MDM2 has been recently reported to extend the Sp1 binding site that positively regulates the MDM2 transcription level and consequently, its expression level. MDM2 is the negative regulator of p53 tumor suppressor protein and elevated levels of MDM2 hamper the stress response driven by the p53 pathway. Whether MDM2-SNP309 was associated with breast cancer as a predisposing factor was investigated. Patients and Methods: A case-control study of 223 females diagnosed with breast cancer and 149 female controls sampled from the Turkish population was carried out and the T/G MDM2-SNP309 genotype of participants was determined. Results: There was no significant association of the G/G or G/T genotypes with breast cancer risk (odds ratio (OR) 1.14, 95% confidence interval (CI) 0.59-2.22, and OR 1.20, 95% CI 0.67-2.12, respectively). Stratification of the data for onset age or for menopausal status at the time of diagnosis also revealed no association for either group.